On May 7, 2024, a CVS Pharmacy logo was spotted at a store in the Florida Keys, symbolizing broader corporate challenges. Glenview Capital, a significant shareholder in CVS Health, is reportedly set to meet the company’s leadership on Monday to propose solutions for the struggling business. This meeting could signal an activist move by the hedge fund, which has amassed a substantial stake in CVS alongside investments in Centene and Teva Pharmaceuticals.
Details about Glenview’s proposals remain undisclosed, but the Wall Street Journal reported that the meeting would include CVS CEO Karen Lynch. A CVS spokesperson emphasized the company’s ongoing dialogue with investors but declined to comment on specific engagements.
CVS shares have declined by 22% year-to-date, reflecting broader investor dissatisfaction. The company previously faced activist interest from Sachem Head Capital Management and Starboard Value. Confidence in CVS waned after three consecutive quarters of lowered full-year guidance, largely due to soaring medical costs in its insurance segment. This trend affects the broader healthcare sector as more seniors resume procedures delayed during the COVID-19 pandemic. CVS’s insurance unit, which includes Aetna plans for the Affordable Care Act, Medicare Advantage, and Medicaid, has struggled significantly.
In August, CVS announced leadership changes, with CEO Lynch taking over the insurance segment from Brian Kane. The company also disclosed plans to cut $2 billion in expenses, streamline operations, and enhance the use of artificial intelligence. Additionally, CVS is nearing the end of a three-year initiative to close 900 stores, with 851 already shut by August.
The retail pharmacy business also faces profitability challenges due to plummeting reimbursement rates for prescription drugs, rising inflation, and diminished consumer spending.
Original Story https://www.cnbc.com/2024/09/30/cvs-activist-glenview-karen-lynch.html
Category :
Tags:
